Phenytoin
Pharmacogenomic Evidence*
An FDA alert on phenytoin and fosphenytoin released on 11/24/2008 reported that the FDA "is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for a particular human leukocyte antigen (HLA) allele, HLA-B*1502." HLA-B*1502 is the same allele associated with increased risk of SJS/TEN in Asian patients taking carbamazepine.
Current phenytoin drug label PDF
Related PharmGKB Resources
| Drug information: | Phenytoin |
|---|---|
| Variants of PGx interest: | HLA-B*1502 |
| Very Important Pharmacogene (VIP) pages: | Not available |
| Allele frequency information: | Not available |
| Gene pages: | HLA-B |
| Gene Variants pages: | HLA-B variants |
| Pathways: | Phenytoin Pathway (PK) |
| Datasets: | Not available |
| Genetics information: | All variant annotations mentioning phenytoin |
| Literature: | Publications related to phenytoin and HLA-B PGx |
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.
The PharmGKB is financially supported by the NIH/
NIGMS and is managed at
Stanford University (U01GM61374).
©2001-2010 PharmGKB.
©2001-2010 PharmGKB.